Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?
2026-07-19 20:12
•Jack Delaney •The Motley Fool
••• ••••• Axe Capital view
Cathie Wood’s Twist Sell-Off: Time to Buy or Pass?
Ark’s trim of Twist Bioscience reflects profit-taking, not panic—worth watching but proceed with caution.
ARKK’s recent sale of $11 million in Twist Bioscience (TWST) amid a 190% rally this year looks like classic profit-taking, not a big loss of faith. ARK still holds over $330 million in the stock, signaling conviction in its synthetic DNA story. For South African investors, this is a gentle reminder to be selective about bio-tech themes. Twist isn’t listed on the JSE, so its local appeal is limited, but the move impacts USD/ZAR dynamics subtly through risk sentiment. If Ark is cashing out gains here to back new ideas like Circle Internet Group and SoFi Technologies, that suggests sectors with tougher valuations might be peaking. For rand investors, watching how these USD-exposed growth plays perform against the rand makes sense. The risk is that the biotech sector remains speculative and loss-making, so big swings persist. If you’re after more grounded JSE names, banks or miners still offer clearer value. this is just my opinion and not financial advice
I’d watch Twist and related biotech names but avoid fresh exposure until losses narrow and valuations stabilize; rand-sensitive growth plays need caution. Stick to JSE staples like Standard Bank or AngloGold Ashanti for steadier ground.
- TWST
- USD/ZAR
- Biotech sector remains highly volatile with ongoing losses
- USD strength could pressure rand-exposed stocks and valuations
6/10
Cathie Wood's Ark ETFs sold over $11 million worth of Twist Bioscience stock on June 30, 2026, despite the synthetic DNA manufacturer's stock climbing 190% year-to-date. The sales appear to be portfolio rebalancing rather than a loss of confidence, as Ark still holds over $332 million in Twist across its ETFs. The proceeds were used to purchase stakes in other companies like Circle Internet Group and SoFi Technologies.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Jack Delaney
Categories: Equities, Earnings, Healthcare
Tickers: TWST, ARKK, ARKG, CRCL, SOFI
Sentiment: Positive - Despite Ark's selling activity, the article emphasizes Ark's substantial remaining holdings ($332M+), strong revenue growth (13 consecutive quarters), and 190% year-to-date gains. The selling is characterized as profit-taking rather than a loss of confidence. However, the article notes the company still reports net losses and carries high risk. The ETF is actively managing its portfolio by selling appreciated positions to fund new investments. This is presented as normal portfolio management strategy rather than positive or negative news.
Keywords: Cathie Wood, Ark ETFs, portfolio rebalancing, synthetic DNA, biotech, stock gains
Insights:
- TWST: Positive: Despite Ark's selling activity, the article emphasizes Ark's substantial remaining holdings ($332M+), strong revenue growth (13 consecutive quarters), and 190% year-to-date gains. The selling is characterized as profit-taking rather than a loss of confidence. However, the article notes the company still reports net losses and carries high risk.
- ARKK: Neutral: The ETF is actively managing its portfolio by selling appreciated positions to fund new investments. This is presented as normal portfolio management strategy rather than positive or negative news.
- ARKG: Neutral: Similar to Ark Innovation ETF, this is executing standard portfolio rebalancing by trimming a large position to reallocate capital.